Prospective randomised controlled trial of the use of nasogastric tubes in patients with adhesive small bowel obstruction (ASBO): protocol for the NASBO study Authors: Ali Al-Mashat, Stephen Ridley Smith, Jon Gani, Christine J O’Neill, David Burnett, Rosemary Carroll, Natalie Lott Published: 2025 ABSTRACT AbstractIntroductionNasogastric tubes (NGTs) are standard practice in the management of adhesive small bowel obstruction (ASBO). Their insertion can be associated with significant patient discomfort and complications. Current research suggests that patients with ASBO managed with NGTs may experience poorer outcomes and higher rates of operative intervention compared with those managed without. However, to date, there are no prospective clinical trials evaluating this.Methods and analysisThis study will be designed as a single centre, prospective, non-inferiority randomised controlled trial to determine if the avoidance of an NGT is non-inferior to its use in ASBO. Patients meeting inclusion criteria will be randomised to either receive an NGT or no NGT for ASBO management. The primary outcome will be the rate of operative intervention as determined by review of medical records at day 30 post discharge. Secondary outcomes will include rate of bowel resection or bowel ischaemia, length of hospital and intensive care unit (ICU) stay, time to operative intervention, rate of ICU admission, incidence of postoperative complications (Clavien-Dindo classification), quality of life scores (European Quality of Life 5 Dimension 5 Level: EQ-5D-5L) at admission, day 30 and day 90, 90-day mortality, incidence of pulmonary complications (Melbourne Group Scale), rate of NGT specific complications and rate of Gastrografin use. The study will be powered at 80% to detect a clinically relevant difference of 10% between groups receiving an NGT compared with no NGT, requiring a total of 490 study participants. Statistical analysis will follow intention to treat principles. Differences between treatment arms will be summarised using mean differences, 95% CIs and p values.Ethics and disseminationThis study has been approved by the Hunter New England Human Research Ethics Committee (2023/ETH00296). Results will be disseminated through peer-reviewed publication and conference presentations.Trial registration numberThis study has been registered prospectively in the Australia and New Zealand Clinical Trials Registry (ACTRN12623000341628).Keywords: SURGERY, Randomized Controlled Trial, Adult surgery STRENGTHS AND LIMITATIONS OF THIS STUDY Prospective randomised controlled study with multicentre potential. Prospective randomised controlled study with multicentre potential. The first prospective clinical trial to compare management with and without a nasogastric tube (NGT) in adhesive small bowel obstruction (ASBO). The first prospective clinical trial to compare management with and without a nasogastric tube (NGT) in adhesive small bowel obstruction (ASBO). Inability to blind patients or clinicians. Inability to blind patients or clinicians. Recruitment may be influenced by patient bias towards NGT use, particularly in repeat ASBO presenters. Recruitment may be influenced by patient bias towards NGT use, particularly in repeat ASBO presenters. Introduction Small bowel obstructions (SBOs) are a common cause for hospital presentation and carry significant patient morbidity and mortality as well as major burdens to healthcare systems worldwide. Intra-abdominal adhesions acquired from previous surgery are the most common cause of SBOs, accounting for 65% of all cases.1 Adhesive small bowel obstructions (ASBOs) alone are responsible for 20% of emergency surgical presentations and 3.3% of laparotomies.2 3 While non-operative management is effective in the majority of ASBO cases,4 surgically managed patients face higher morbidity and mortality, with greater financial and hospital burdens, especially if surgical intervention is delayed.5,7 The mainstay of non-operative management in ASBO has been widely accepted as intestinal decompression via a nasogastric tube (NGT) and is recommended by the Bologna Guidelines from the World Journal of Emergency Surgery alongside other conservative measures including intravenous fluids, nil per oral and water soluble contrast administration.4 Despite their widespread use, the clinical value of NGTs remains uncertain. An Australasian survey on SBO management (unpublished data) shows that surgeons commonly use NGTs for their perceived therapeutic benefits, including resolving ASBO, preventing surgery, reducing aspiration risk, facilitating Gastrografin administration and alleviating symptoms such as distension, pain and vomiting. However, NGTs can lead to complications and significant patient discomfort.8 9 Several retrospective studies suggest that NGTs may not be achieving their intended benefits in ASBO management. Berman et al found that NGT decompression did not reduce the need for surgery or bowel resection but was associated with a 2-day increase in hospital stay.10 Fonseca et al reported that NGT use was significantly associated with pneumonia, respiratory failure, delayed ASBO resolution and longer hospital stays.11 Shinohara et al observed no significant differences in outcomes such as vomiting, pneumonia or surgery rates between patients managed with and without NGTs.12 Furthermore, a yet published 5-year retrospective study conducted locally at John Hunter Hospital demonstrated that NGT use was associated with increased rates of operative intervention (36% of patients with NGTs vs 7% without), longer hospital stays (6.9 vs 3.2 days) and longer time to surgical intervention (58.8 vs 19.4 hours). These studies are limited by their retrospective design, which cannot determine whether the outcomes were caused by NGT use or by the selection of sicker patients. To address this, a prospective clinical trial is needed. From our review of the literature, there are no published prospective trials to date comparing NGT use against management without an NGT in ASBO. As Owen Wangensteen, renowned for his work on intestinal obstruction and recipient of the Samuel Gross Prize, stated, the true value of this method will only become apparent through wide clinical trial.13 14 This paper outlines a protocol for a prospective, non-inferiority, randomised controlled trial evaluating the role of NGT use in preventing operative intervention and improving outcomes in ASBO management. The non-inferiority margin was pre-specified at 10%, based on retrospective local data and an Australasian surgeon survey indicating this threshold as the clinically acceptable difference in operative intervention rates between management strategies. We hope that the results of this study will guide the establishment of updated treatment protocols to better guide surgeons in the management of ASBO; improving and optimising non-operative management and operative prevention. Methods This study will be designed as a single-centre, non-inferiority, randomised controlled trial, with the potential to expand to a multicentre study across collaborating hospital sites in Australia. Participating sites will be determined from expressions of interest collected in a survey on SBO management administered through General Surgeons Australia (GSA) during 2021 and 2022. The recruitment period is planned to span 4 years, initially commencing in December of 2023 at John Hunter Hospital, Newcastle, New South Wales, Australia. The study has been registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12623000341628). The research will involve individuals with clinically and radiologically confirmed ASBO with a history of previous abdominal surgery, who present directly to the Emergency Department (ED) of the designated participating surgical centre equipped with acute general surgical services. Patient recruitment will be facilitated by the on-call surgical registrar, receiving referrals from ED personnel briefed in advance about the trial through departmental meetings and presentations at clinical handover. After confirming eligibility and obtaining written informed consent using the attached form (online supplement 1), patients will be randomised within 6 hours of radiologically confirmed ASBO to one of two groups: Control group: NGT insertion. Control group: NGT insertion. Interventional group: No NGT insertion. Interventional group: No NGT insertion. Eligible participants will be randomised using the Research Electronic Data Capture (REDCap) database, through a computer-based randomisation schedule generated by an online website.15 Treatments will be allocated in equal ratios (1:1) within stratum using permuted blocks of size 4. There will be one stratum based on treatment site. Due to the nature of the intervention, there will be no blinding of patients, the surgical team or assessors in this trial. However, an independent biostatistician, blinded to study outcomes and treatment allocation, will analyse the data. Once randomised, baseline characteristics will be obtained from the study participants. If allocated to the interventional group, the NGT insertion procedure will be performed by a qualified member of the healthcare team, in accordance with local policies and guidelines, and confirmed by a chest radiograph. The remainder of clinical management will be as per the treating surgical team. The decision to proceed with operative intervention will be determined by the treating consultant surgeon, based on clinical, radiological and biochemical findings indicative of failure of non-operative management. This may include persistent or worsening abdominal pain, clinical or radiological evidence of bowel ischaemia, perforation, or closed-loop obstruction, or failure to demonstrate resolution of obstruction after an appropriate trial of conservative management (typically 72 hours). Outcome measures will be assessed at day 30 and day 90 post discharge by review of medical records and telephone follow-up. Table 1 outlines the major time points of this study. Data related to protocol deviations will be recorded, particularly if a patient assigned to the no-NGT group has an NGT inserted after randomisation due to clinical deterioration, pre-operative preparation or persistent vomiting. Patients who receive an NGT during the pre-randomisation period will be excluded from the study. If an NGT is inserted post-randomisation, the patient will remain in the trial and be analysed according to the intention-to-treat principle. These instances will be documented as protocol deviations and reported accordingly. Table 1Study time pointsAdmission to siteDuring inpatient admission30-day post discharge follow-up90-day post discharge follow-upScreening for eligibility√Baseline characteristics(including Charlson Comorbidity Index)Medical imaging√Informed consent√Within 6 hours of first surgical review√(Written consent if required by discharge)Randomisation√Within 6 hours of diagnosis of ASBOAssessment of need for operative intervention+/−bowel resection and postoperative complications (Clavien-Dindo classification)aAssessment ofpulmonary complications (Melbourne Group Scale)16aAssessment of medical morbidityaAssessment of readmission with ASBO recurrenceaMortalityaQuality of Life(European Quality of Life 5 Dimension 5 limit score)17aaaASBO, adhesive small bowel obstruction. Study time points ASBO, adhesive small bowel obstruction. Patient and Public Involvement Patients and members of the public were not involved in the design of this trial. The protocol was reviewed by an independent healthcare professional to ensure clarity and methodological soundness. Eligibility criteria Inclusion criteria Patients who will be included in this study will need to meet the following criteria: Age 18 years or older. Age 18 years or older. Written informed consent provided from the patient or person responsible. Written informed consent provided from the patient or person responsible. Direct presentation to a participating hospital site with an ASBO. Direct presentation to a participating hospital site with an ASBO. A history of previous abdominal or pelvic surgery. A history of previous abdominal or pelvic surgery. Radiological evidence of an ASBO in the form of a dedicated CT Abdomen and Pelvis (CTAP) scan reported by a board-certified radiologist. Radiological evidence of an ASBO in the form of a dedicated CT Abdomen and Pelvis (CTAP) scan reported by a board-certified radiologist. Exclusion criteria Patients will be excluded from this study if any of the following apply: Are unable to provide written informed consent, or do not have a designated person responsible to provide substitute consent. Are unable to provide written informed consent, or do not have a designated person responsible to provide substitute consent. Enrolment in the study within the last 3 months. Enrolment in the study within the last 3 months. Are unable to provide informed consent due to language barriers, where a suitable interpreter is not available. Are unable to provide informed consent due to language barriers, where a suitable interpreter is not available. Admission to the participating site via transfer from another hospital. Admission to the participating site via transfer from another hospital. Has had an NGT inserted prior to randomisation. Has had an NGT inserted prior to randomisation. Intestinal obstruction with any aetiology other than adhesions, that is, malignancy, hernia, inflammatory bowel disease, foreign body, intussusception or large bowel obstruction. Intestinal obstruction with any aetiology other than adhesions, that is, malignancy, hernia, inflammatory bowel disease, foreign body, intussusception or large bowel obstruction. ASBO in patients with a known gastrointestinal malignancy. ASBO in patients with a known gastrointestinal malignancy. Patients with a pseudo-obstruction or paralytic ileus. Patients with a pseudo-obstruction or paralytic ileus. Where initial non-operative management is contraindicated, that is, patients requiring urgent emergency surgery due to peritonism, strangulation or radiological evidence of bowel ischaemia or perforation. Where initial non-operative management is contraindicated, that is, patients requiring urgent emergency surgery due to peritonism, strangulation or radiological evidence of bowel ischaemia or perforation. Pregnancy at the time of presentation with ASBO. Pregnancy at the time of presentation with ASBO. Diagnosed with pneumonia within the last 3 months. Diagnosed with pneumonia within the last 3 months. Considered to not have a survivable condition on admission. Considered to not have a survivable condition on admission. Collected variables Baseline characteristics will include age, sex, Body Mass Index (BMI), comorbidities (assessed using the Charlson Comorbidity Index score), smoking status within the past 12 months, identification as Aboriginal or Torres Strait Islander, diabetic status, cardiovascular comorbidities, nature of prior abdominal surgery and history of prior ASBO. For both groups, whether water-soluble contrast was administered will be noted, although this is expected to be routine. For participants assigned to the NGT group, the type of NGT maintenance (ie, low-wall suction, free drainage or intermittent manual aspiration), duration of NGT insertion and reason for NGT removal will be collected. Outcome measures The primary outcome of this study will be the rate of operative intervention in the management of ASBO as determined by review of medical records at day 30 post discharge. Secondary outcomes will include: Rate of bowel resection or intra-operative findings of bowel necrosis. Rate of bowel resection or intra-operative findings of bowel necrosis. Mean time to operative intervention (hours) as determined from the time of admission. Mean time to operative intervention (hours) as determined from the time of admission. Rate of return to the operating theatre after initial operative intervention. Rate of return to the operating theatre after initial operative intervention. Mean hospital and intensive care unit length of stay (days) assessed at day 90. Mean hospital and intensive care unit length of stay (days) assessed at day 90. Rate of admission to the intensive care unit.Incidence of postoperative surgical complications, classified according to the Clavien-Dindo system, identified within 30 days after discharge through review of medical records and patient self-report during telephone follow-up. Rate of admission to the intensive care unit. Incidence of postoperative surgical complications, classified according to the Clavien-Dindo system, identified within 30 days after discharge through review of medical records and patient self-report during telephone follow-up. Incidence of vomiting as determined by review of medical records or as reported by the patient during the 30-day telephone follow-up.Incidence of pulmonary complications, graded according to the Melbourne Group Scale.16 These may include findings such as chest X-ray evidence of collapse or consolidation, new production of yellow or green sputum, or prescription of antibiotics for a respiratory infection. Incidence of vomiting as determined by review of medical records or as reported by the patient during the 30-day telephone follow-up. Incidence of pulmonary complications, graded according to the Melbourne Group Scale.16 These may include findings such as chest X-ray evidence of collapse or consolidation, new production of yellow or green sputum, or prescription of antibiotics for a respiratory infection. Incidence of any NGT specific complications, by review of medical records at day 90. Incidence of any NGT specific complications, by review of medical records at day 90. Incidence of medical events, including electrolyte disturbances, venous thromboembolism, myocardial infarction and acute kidney injury, as identified through review of medical records and patient self-report during the 30-day telephone follow-up. Incidence of medical events, including electrolyte disturbances, venous thromboembolism, myocardial infarction and acute kidney injury, as identified through review of medical records and patient self-report during the 30-day telephone follow-up. Quality of life score assessed at admission, day 30 and 90 post discharge using the European Quality of Life 5 Dimension 5 Limit (EQ-5D-5L) score.17 Quality of life score assessed at admission, day 30 and 90 post discharge using the European Quality of Life 5 Dimension 5 Limit (EQ-5D-5L) score.17 Rate of use of low continuous suction applied to the NGT. Rate of use of low continuous suction applied to the NGT. Rate of use of Gastrografin. Rate of use of Gastrografin. 90-day mortality. 90-day mortality. Adverse events and adverse event reporting Adverse events in this trial will be defined as any medical occurrence that results in death, is life-threatening, requires hospitalisation or prolonged hospitalisation, causes significant disability, or is a medically important event. This study involves the randomisation of two acceptable management strategies for ASBO. While adverse events may not necessarily have a causal relationship with the randomised treatment, they will be recorded for both the interventional and control groups and reported accordingly. Statistical analysis Based on a retrospective audit of patients admitted to John Hunter Hospital over a 5-year period with ASBO (operation rate 23%) and an Australasian surgeon survey (unpublished) suggesting a clinically relevant non-inferiority margin of 10%, a sample size of 220 patients per arm is required (80% power, type 1 error 5%). Allowing for a 10% attrition rate, the study will aim to recruit 490 patients across participating sites. The analysis of the efficacy endpoint will be conducted on the full analysis set and will include all participants who were randomised in the study. The analysis will follow intention-to-treat principles, analysing patients according to the treatment they were randomised to receive. Baseline characteristics of patients will be summarised by treatment group. The means will be compared between groups using a linear regression model, with the stratification variable as a covariate, along with any potential unbalanced baseline variables. The primary strategy for dealing with missing data will be multiple imputation using the chained regression equations method. Pooled least square mean differences, 95% CIs and p values will be presented for the differences between treatment arms. Secondary outcomes will be compared between groups using a generalised linear model with an appropriate distribution and link function depending on the type of outcome. Data management and monitoring An independent Data Safety and Monitoring Board (DSMB) consisting of a surgeon, anaesthetist and biostatistician will review all monitoring and reporting of adverse events to the Hunter New England Human Research Ethics Committee (HREC). There will be no interim analysis in this project. A study database will be used to store data via the Hunter Medical Research Institute (HMRI) REDCap system. The data will be encrypted and password protected, with access provided to research staff through two-factor authenticated accounts. An investigator at each participating site will oversee patient enrolment in the study and monitor adherence to the protocol. If at any point a patient no longer wishes to participate in the study, they will be withdrawn, including their data. Ethics and dissemination This trial has been granted approval by the Hunter New England HREC (2023/ETH00296). Any amendments made to the protocol will be submitted to the HREC for review. On completion, the data will be analysed and disseminated through peer-reviewed publication and conference presentations. Supplementary material Footnotes Funding: This project will be funded and sponsored internally by the relevant hospital institution (John Hunter Hospital). Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2024-097986). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study. No data are available. References Supplementary Materials Data Availability Statement Data sharing not applicable as no datasets generated and/or analysed for this study. No data are available.